Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dapsone,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Cosette Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone 5%
Details : Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.
Product Name : Aczone-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Dapsone,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Cosette Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapsone,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2016
Lead Product(s) : Dapsone,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
